Confluence Pharmaceuticals Overview
- Year Founded
-
2010
- Status
-
Private
- Employees
-
4
- Latest Deal Type
-
Series B
- (In Progress)
- Latest Deal Amount
-
$1.1M
- Investors
-
6
Confluence Pharmaceuticals General Information
Description
Developer of therapeutic medications intended to treat rare orphan neurological disorders. The company's medications offer clinically-discovered treatment for core social and communication impairments caused by fragile X syndrome and autism spectrum disorders and benefit similarly anchored disorders like Rett Syndrome and Treatment-Resistant Anxiety, enabling healthcare providers to treat their patients and improve their lives.
Contact Information
Website
www.confluencepharma.comCorporate Office
- 27628 Will Parker Road
- Arcadia, IN 46030
- United States
Corporate Office
- 27628 Will Parker Road
- Arcadia, IN 46030
- United States
Confluence Pharmaceuticals Timeline
Confluence Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 10. Later Stage VC (Series B) | 25-Aug-2023 | $1.1M | In Progress | Clinical Trials - General | ||
| 9. Later Stage VC | 10-Feb-2023 | Completed | Clinical Trials - General | |||
| 8. Later Stage VC (Series B1) | 28-Feb-2022 | Completed | Clinical Trials - General | |||
| 7. Later Stage VC (Series B) | 13-Sep-2021 | Completed | Clinical Trials - General | |||
| 6. Later Stage VC | 18-Nov-2020 | Completed | Clinical Trials - General | |||
| 5. Debt - General | 16-Jul-2020 | Completed | Clinical Trials - General | |||
| 4. Later Stage VC (Series B) | 24-Feb-2020 | Completed | Clinical Trials - General | |||
| 3. Later Stage VC (Series B) | 01-Mar-2019 | Completed | Clinical Trials - General | |||
| 2. Later Stage VC (Series A2) | 07-Nov-2017 | $1.6M | $4.2M | Completed | Clinical Trials - General | |
| 1. Early Stage VC (Series A1) | 01-Nov-2013 | $2.6M | $2.6M | Completed | Pre-Clinical Trials |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Confluence Pharmaceuticals Comparisons
Industry
Financing
Details
Confluence Pharmaceuticals Competitors (12)
One of Confluence Pharmaceuticals’s 12 competitors is Minerva Neurosciences, a Formerly VC-backed company based in Burlington, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Minerva Neurosciences | Formerly VC-backed | Burlington, MA | ||||
| NeuroDerm | Formerly VC-backed | Rehovot, Israel | ||||
| Marinus Pharmaceuticals | Private Equity-Backed | Radnor, PA | ||||
| Vertex Pharmaceuticals | Formerly VC-backed | Boston, MA | ||||
| Zynerba Pharmaceuticals | Formerly VC-backed | Plymouth, PA |
Confluence Pharmaceuticals Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Confluence Pharmaceuticals Patents
Confluence Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20200163895-A1 | Formulations of homotaurines and salts thereof | Active | 17-May-2017 | ||
| AU-2021225172-A1 | Formulations of homotaurines and salts thereof | Active | 17-May-2017 | ||
| AU-2018269557-B2 | Formulations of homotaurines and salts thereof | Active | 17-May-2017 | ||
| AU-2018269557-A1 | Formulations of homotaurines and salts thereof | Active | 17-May-2017 | ||
| CA-3062834-A1 | Formulations of homotaurines and salts thereof | Pending | 17-May-2017 | A61P25/00 |
Confluence Pharmaceuticals Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Confluence Pharmaceuticals Investors (6)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Indiana 21st Century Research and Technology Fund | Government | Minority | ||
| Foundry Partners | Asset Manager | Minority | ||
| Angel (individual) | Minority | |||
| Foundry Investment Fund | Not-For-Profit Venture Capital | Minority | ||
| IU Ventures | Corporate Venture Capital | Minority |
Confluence Pharmaceuticals FAQs
-
When was Confluence Pharmaceuticals founded?
Confluence Pharmaceuticals was founded in 2010.
-
Where is Confluence Pharmaceuticals headquartered?
Confluence Pharmaceuticals is headquartered in Arcadia, IN.
-
What is the size of Confluence Pharmaceuticals?
Confluence Pharmaceuticals has 4 total employees.
-
What industry is Confluence Pharmaceuticals in?
Confluence Pharmaceuticals’s primary industry is Drug Discovery.
-
Is Confluence Pharmaceuticals a private or public company?
Confluence Pharmaceuticals is a Private company.
-
What is Confluence Pharmaceuticals’s current revenue?
The current revenue for Confluence Pharmaceuticals is .
-
How much funding has Confluence Pharmaceuticals raised over time?
Confluence Pharmaceuticals has raised $8.83M.
-
Who are Confluence Pharmaceuticals’s investors?
Indiana 21st Century Research and Technology Fund, Foundry Partners, , Foundry Investment Fund, and IU Ventures are 5 of 6 investors who have invested in Confluence Pharmaceuticals.
-
Who are Confluence Pharmaceuticals’s competitors?
Minerva Neurosciences, NeuroDerm, Marinus Pharmaceuticals, Vertex Pharmaceuticals, and Zynerba Pharmaceuticals are some of the 12 competitors of Confluence Pharmaceuticals.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
